Fuzuloparib

Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. It is approved for use in China. It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme.

It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer.